Buy (tactical/short-term): Price is sitting right on key support (~19.38) with an extremely oversold RSI (6) near 4.4, which often precedes sharp snapback rallies.
Derivatives sentiment is bullish (put/call ratios ~0.5) with elevated activity, supporting a near-term rebound attempt.
Wall Street is constructive with multiple Buy ratings and $37 targets (large upside vs ~$19), reinforcing dip-buying interest.
Not a trend-following buy: the primary trend is still bearish (MACD worsening; MAs stacked bearishly), so this is best viewed as a mean-reversion entry “right now”, not confirmation of a sustained uptrend.
Positioning/Activity: Today’s volume 779 and volume vs 30D avg 148% → active participation.
Volatility: IV (30D) 87.44 vs HV 114.56; IV percentile 87.5 / IV rank 88.29 → options are pricing elevated uncertainty (consistent with big moves after sharp selloffs).
Open interest: Calls OI 1560 vs puts OI 799 → call-heavy positioning supports rebound expectations.
Technical Summary
Sell
9
Buy
6
Positive Catalysts
near first support (~19.
supports a reflex rally setup.
Neutral/Negative Catalysts
is at/slightly below S1 19.376; a clean break increases risk of a move toward S2 16.876.
Financial Performance
Latest quarter: 2025/Q3
Revenue: $8.918M (reported as 0.00% YoY change in the snapshot).
2025-12-17 (BofA): Buy maintained; PT raised $35 → $37 after first post-IPO earnings; cites stronger results and partnerships.
2025-11-30 (Jefferies): Initiated Hold, PT $30; likes multi-aircraft approach but wants more progress before upgrading.
Wall Street view (pros/cons):
Pros: Multiple Buys and rising targets signal improving confidence; PTs imply substantial upside vs ~$19.
Cons: At least one major shop remains on Hold pending proof of execution; near-term stock action is still technically bearish.
Wall Street analysts forecast BETA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BETA is 36.17 USD with a low forecast of 30 USD and a high forecast of 42 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast BETA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BETA is 36.17 USD with a low forecast of 30 USD and a high forecast of 42 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 15.800
Low
30
Averages
36.17
High
42
Current: 15.800
Low
30
Averages
36.17
High
42
Truist
Richard Newitter
Buy
maintain
$32 -> $37
AI Analysis
2025-12-18
Reason
Truist
Richard Newitter
Price Target
$32 -> $37
AI Analysis
2025-12-18
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Beta Bionics to $37 from $32 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.
BofA
Buy
maintain
$35 -> $37
2025-12-17
Reason
BofA
Price Target
$35 -> $37
2025-12-17
maintain
Buy
Reason
BofA raised the firm's price target on Beta Technologies to $37 from $35 and keeps a Buy rating on the shares after the company reported their first earnings since going public on November 3. The firm's raised target reflects increased revenue estimates from stronger results and partnerships, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BETA
